



IVI Updates RA Value Assessment Model to Account for Latest Treatment Options

Nonprofit Seeks Data Partners to Take Models Even Further to Address Questions Relevant to Patients and Payers

Alexandria, VA – January 7, 2020 – The Innovation and Value Initiative (IVI), a non-profit research organization dedicated to improving the science and practice of value assessment, today released an updated version of its prototype economic model that examines value among rheumatoid arthritis (RA) therapies. The model, IVI-RA, helps decision makers identify high-value therapies by simulating the lifetime costs and benefits of different strategies for treating patients with moderate to severe RA. The latest research also highlights the type of additional questions important for patients, providers, and payers that could be further answered by the model with the addition of real-world data.

The new model release incorporates additional treatment options (triple therapy, Janus Kinase (JAK) inhibitors sarilumab, and biosimilars), updated treatment effect estimates based on additional randomized controlled trial (RCT) evidence, and updated cost estimates.

IVI's model is also designed to measure for a variety of factors important to patients, payers, and providers such as: the role of additional adverse events; the time to treatment discontinuation; patient preferences; and treatment effects after treatment failure. When given real world patient data as an input, the model can answer a wide variety of questions related to these factors and more.

“Value assessments must be relevant to real-world decision makers and can be vastly improved by an ability to showcase how real patients experience disease,” says Jennifer Bright, IVI's executive director. “We recognize that our open-source model is just a start, which is why we are calling for partners to work with us, sharing real-world data on outcomes so we can answer even more questions. Our aim is to perfect this model to answer questions truly important to patients, providers, and payers.”

IVI-RA was the first disease-specific economic model developed within IVI's Open-Source Value Project (OSVP), which serves as a laboratory for developing next-generation economic models in an open-source environment. The model was initially released in November 2017.

All IVI models go through a rigorous review and update process to ensure they remain relevant over time and evolve with the most current body of treatments, evidence, and scientific insight.

IVI will continue to update the model in 2020, including to examine duration of maintenance treatment and the impact of prior treatment.

“We believe value assessment shouldn’t be a static process – it should be an open and iterative process involving all healthcare decision-makers,” says Bright. “The more collaboration and real-world data we have from partners, the more we can continue to evolve a model. That’s why our focus in 2020 is working with partners — researchers, health plans, data analytic concerns — who are equally committed to better answers.”

###